Skip to main content
MBX
NASDAQ Life Sciences

MBX Posts $62.4M Q3 Loss; $481.6M Cash Funds Runway Into 2029

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Neutral
Importance info
7
Price
$53.31
Mkt Cap
$2.604B
52W Low
$21.9
52W High
$72.64
52W Position info
143% above low
Off High info
27% below high
Rel. Volume info
1.3× avg
Market data snapshot near publication time

MBX has more than doubled off its 52-week low of $21.9.

Summary

MBX reported a $62.4M Q3 2026 net loss, inflated by $20.8M of former-CEO stock comp, while holding $481.6M in cash that funds operations into 2029. The Phase 3 hypoparathyroidism trial is enrolling and 12-week obesity data for MBX 4291 is due in Q4 2026.


Key Events · Earnings and Guidance · MBX

  • Q3 Net Loss Widens to $62.4M

    Net loss was $62.4M versus $21.6M in Q3 2025, with loss per share of $1.29 versus $0.63.

  • Cash Runway Extended Into 2029

    Cash, cash equivalents and marketable securities totaled $481.6M at September 30, 2026, including $97.6M of net ATM proceeds during the quarter.

  • Former-CEO Stock Comp Drives G&A

    G&A rose to $34.3M from $4.7M, including $20.8M of stock-based compensation from modifying the former chief executive officer's awards.

  • Phase 3 Enrollment Underway

    The pivotal Phase 3 oPTimize trial of once-weekly canvuparatide in chronic hypoparathyroidism is enrolling roughly 160 adults after first patient dosing in August 2026.


Analysis · MBX · Life Sciences

The quarter's headline is the swing to a $62.4M net loss from $21.6M a year ago, but most of the damage is accounting, not cash burn: G&A jumped to $34.3M largely on $20.8M of stock-based compensation tied to modifying the former CEO's awards, and R&D rose to $32.0M as the canvuparatide Phase 3 oPTimize trial started. The balance sheet is the real story — $481.6M in cash after $97.6M of ATM proceeds keeps funding through 2029, so the Phase 3 readout and the Q4 2026 MBX 4291 12-week MAD obesity data are financed without another raise. That removes near-term financing risk, which is why this matters more than a routine quarterly print.

How filings like this one have moved

In the 30 days to Nov 9, 2026, 36.6% of the 2965 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, MBX was trading at $53.31 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.6B. The 52-week trading range was $21.90 to $72.64. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

MBX - Latest Insights

MBX
Nov 09, 2026, 4:01 PM EST
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $53.31
Real-time Price: $53.31 info
Change: $0 (0%) info
Market Cap: $2.604B info
MBX
Aug 27, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $66.50
Real-time Price: $53.31 info
Change: -$13.19 (-20%) info
Market Cap: $2.604B info
MBX
Aug 10, 2026, 4:44 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
7
Price at Filing: $66.15
Real-time Price: $53.31 info
Change: -$12.84 (-19%) info
Market Cap: $2.604B info
MBX
Aug 06, 2026, 8:06 AM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $67.80
Real-time Price: $53.31 info
Change: -$14.49 (-21%) info
Market Cap: $2.604B info
MBX
Aug 06, 2026, 8:03 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $67.80
Real-time Price: $53.31 info
Change: -$14.49 (-21%) info
Market Cap: $2.604B info